The TIGRIS clinical trial is a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion #PMX in a randomized controlled trial of adults treated for endotoxemia and septic shock. The trial methods are detailed in “Bayesian methods: a potential path forward for sepsis trials”. https://lnkd.in/g8zcUzub
Spectral Medical Inc.’s Post
More Relevant Posts
-
Today, we shared an update on the SAB-142 trial for #type1diabetes: we have completed dosing the third cohort for SAB-142 with no observation of serum sickness thus far. For further information, please see our press release here: https://lnkd.in/eJbT74hd. Phase 1 of SAB-142 is a randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous SAB-142 in healthy volunteers and participants with T1D. SAB-142 is a first-in-class human anti-thymocyte immunoglobulin being developed as a disease-modifying treatment to delay the onset and progression of T1D.
To view or add a comment, sign in
-
Regional Director Vascular DACH bei Abbott | Business Management, Analytical Skills, Sales and Marketing
The LIFE-BTK Study is a prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the investigational Esprit™ BTK Everolimus Eluting Resorbable Scaffold System vs percutaneous transluminal angioplasty (PTA)† for the treatment of infrapopliteal arterial disease in patients with chronic limb-threatening ischemia (CLTI). Prospective, randomized, multicenter trial across 50 Global Sites 261 patients randomized (2:1 Esprit™ BTK System vs. PTA†) Esprit™ BTK System (n=173) PTA† (n=88) https://lnkd.in/ewM42Zr7 #BTK #endovasuclar #CLTI #PTA #proudtobeabbott #ESPRITBTK
To view or add a comment, sign in
-
International Medical Director | Physician - Scientist | HBR Advisory Council | Top Strategic Communications Voice | MD MSc MScID MBA FRSPH FRSA
The use of SCO-101 plus leucovorin, fluorouracil, and irinotecan (FOLFIRI) was found to increase efficacy and maintain safety and tolerability for a small cohort of patients with metastatic #colorectalcancer (CRC), according to results from part 3 of the phase 2a CORIST #clinicaltrial (NCT04247256). In part 3, the median progression-free survival (PFS) was 4.6 months, and after 8 weeks of treatment, the clinical benefit rate (CBR) was 76%. The PFS in part 2 was 2.0 months, and the CBR was 46%. https://lnkd.in/e2fNRT9X
To view or add a comment, sign in
-
📉 In this multicenter, randomized, double-blind, placebo-controlled, two-by-two factorial trial conducted in China, patients with acute Mild Ischemic Stroke or High-risk TIA of presumed atherosclerotic origin who received combined CLOPIDOGREL and ASPIRIN within 72 hours after symptom onset had a risk of stroke at 90 days that was approximately 2 percentage points lower than the risk with aspirin alone. 📈 The risk of moderate-to-severe bleeding was approximately twice as high in the clopidogrel–aspirin group as in the aspirin group, although this risk was low in both groups.
To view or add a comment, sign in
-
FSGS causes scarring in the kidney's blood-filtering cells, leading to protein leakage and potential kidney failure. We're seeking participants for RDRI's FSGS Clinical Trial, aiming to reduce protein loss in the urine and preserve kidney function. If diagnosed with FSGS, discuss with your doctor and consider joining this important study. Help us advance treatment options for this serious condition. #FSGS #ClinicalTrials #KidneyHealth
To view or add a comment, sign in
-
Abnormal RBC parameters can pose a challenge in daily laboratory routines 🩸🔬. At the same time, there is a need for reliable diagnosis of haemoglobinopathies and red cell membrane disorders from other causes of abnormalities in RBC indices. Using the RBC Defect Workflow Optimisation rules in Sysmex 𝘌𝘹𝘵𝘦𝘯𝘥𝘦𝘥 IPU can help you identify the respective sample, allowing you to perform confirmatory tests for the likely disease and save time and resources in the lab ⌚. What’s more - if you suspect haemoglobinopathies or sickle cell disease, the Tosoh G11 β-Thalassemia mode can help confirm these and provide quantification of HbA2 and HbF and detect other possible Hb variants. Discover how to verify this and improve patient management at: https://lnkd.in/e9t_Hgiz #sysmexnordic #tosoh
To view or add a comment, sign in
-
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
To view or add a comment, sign in
-
2004 marked two milestones for TauroLock™. 🎉 It was not only the year when our product officially entered the market: At the same time, we also saw the publication of the first randomised clinical trial on its antimicrobial efficacy. 💡 Betjes et al. compared the use of TauroLock™ and heparin in haemodialysis patients. Their findings led them conclude that: ✔️ TauroLock™ is “effective and safe” (1) for the prevention of catheter-related sepsis (CRS). ✔️ TauroLock™ can significantly reduce the rate of CRS, even in dialysis centres using heparin with an already low incidence rate. (1) #tauropharm #taurolock #taurolidne #antimicrobial #infectionprevention #dialysis 1) Betjes et al. Nephrol Dial Transplant 2004. DOI: 10.1093/ndt/gfh014
To view or add a comment, sign in
-
(4/9) PI3Kα-Driven Vascular Malformations is the first of two programs in #geneticdisease that we unveiled today. #Vascularmalformations are a series of rare syndromes that occur due to atypical development of lymphatic and/or blood vessels, of which mutant PI3Kα is the most common driver. There are over ~170,000 patients with PI3Kα-driven vascular malformations in the U.S. We believe our mutant-selective PI3Kα inhibitor, RLY-2608, provides the opportunity for greater target coverage, leading to the potential for improved efficacy and better chronic tolerability for these patients. We plan to initiate clinical development in Q1 2025.
To view or add a comment, sign in
-
Editor's choice! 📖 Epirubicin for DEB-TACE: Prospective, single-arm, multicentre study on 108 patients with HCC that were treated with small size Edirubicin eluting beads in 199 procedures reveals satisfactory 12 month oncologic outcomes with no unanticipated adverse events. However, 30 serious adverse events occurred including five cases of hepatic abscess formation. https://lnkd.in/dg3HR-4e
To view or add a comment, sign in
2,484 followers